CI
Cigna GroupEvidence as of 2026-09-02Overview · Cigna Group
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and he…
Management team
- Ms. Jamie Kates · Chief Accounting OfficerFind on LinkedIn
- Mr. Eric Paul Palmer · Executive Vice President of Enterprise StrategyFind on LinkedIn
- Ms. Nicole Susan Jones J.D. · Executive VP, Chief Administrative Officer & General CounselFind on LinkedIn
- Ms. Noelle K. Eder · Executive VP & Global Chief Information OfficerFind on LinkedIn
Start your 7-day free trial to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it — not a rating or a recommendation.
+0.4 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled — the rest of the page is the evidence behind it.
What the evidence shows
The evidence balance is constructive (+0.4 of a possible +2; was +0.4 before debate) with high confidence. Revenues rose from $65,502,000,000 in the fiscal Q1 2025 (2025-01-01 to 2025-03-31, 3mo) to $71,668,000,000 in the fiscal Q2 2026 (2026-04-01 to 2026-06-30, 3mo), while operating income increased from $1,971,000,000 to $2,676,800,000 over the same span. Net income moved from $1,323,000,000 to $1,660,000,000 and diluted EPS from $4.85 to $6.29; reported common shares outstanding declined from 278,152,606 to 264,240,486 shares, and repurchases are reported at $1,508,000,000 in the filed instances. Market and valuation context shows a trailing P/E of 11.21, EV/EBITDA of 8.57 (EBITDA TTM $12,602,000,000; enterprise value $108,020,911,967), a market price of 283.06 and market cap of $74,795,911,967, with modest dividend yield of 2.17% and beta to SPY of 0.20.
What the debate changed
No surviving claims were dropped or materially weakened in the discussion, so the desk kept the original read intact. The analytical contest did not remove any central factual points; the evidence set remains weighted toward financial-statement movements, headline product-launch coverage, limited insider sales, and unparsed Form 4 filings dated 2026-08-20.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else — no outside knowledge, no browsing — so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC — revenue, margins, income, debt and share count, quarter by quarter — and reports which way the trend is running.
Revenues increased from $65,502,000,000 in the fiscal Q1 2025 (2025-01-01 to 2025-03-31, 3mo) to $71,668,000,000 in the fiscal Q2 2026 (2026-04-01 to 2026-06-30, 3mo).
XBRL companyfacts · 0001739940-25-000021Operating income rose from $1,971,000,000 in the fiscal Q1 2025 (2025-01-01 to 2025-03-31, 3mo) to $2,676,800,000 in the fiscal Q2 2026 (2026-04-01 to 2026-06-30, 3mo).
XBRL companyfacts · 0001739940-25-000021Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Which filings the desk reads
The desk reads the annual 10-K in full — its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet — its risk analysis fills in once that lands.
Two Form 4 insider transaction reports for Cigna Group were filed on 2026-08-20.
4 filed 2026-08-20Two Form 4 insider transaction reports for Cigna Group were filed on 2026-08-20.
4 filed 2026-08-20Reads the signal panel above — momentum, volatility, drawdown, relative strength and beta — and ranks each against the whole research universe rather than judging it in isolation.
Momentum readings are small positives: 3-month +4.4%, 6-month +0.8%, and 12-month (12_1) +7.8%, but momentum percentiles are below the median (rank_momentum_6m: 39th percentile of 547; rank_momentum_12_1: 44th percentile of 547).
Moneyta signal set · 2026-09-01weakened in debateTechnical trend signals show a golden cross in place with price slightly above the 200-day SMA (price_vs_sma200: +2.0%) and price essentially at the 50-day SMA (price_vs_sma50: -0.1%) after the cross_age_days of 60.
Moneyta signal set · 2026-09-01Reads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
13F-reported institutional holders held a total of $153.6M in the position as of 2026-03-31 (13F filings carry a 45-day reporting lag).
13F holdings · 2 filers · as of 2026-03-31Ensign Peak Advisors, Inc is shown as a top holder with $140.7M reported as of 2026-03-31, a quarter-over-quarter change of -3.0%.
13F holdings · 2 filers · as of 2026-03-31Reads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
Multiple outlets report Cigna Group launched a “connected benefits” solution that links medical and supplemental coverage for employees on high-deductible health plans to simplify claim matching and speed access to cash benefits.
News · simplywall.st · 2026-08-30Several articles frame Cigna as undervalued or a strong value stock based on market multiples and value scores.
News · zacks.com · 2026-08-31Reads parsed Forms 3/4/5 — who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
On 2026-08-18, Jones Nicole S reported selling 2,677 shares for a total value of "$749k".
Form 4 · Jones Nicole S (See Remarks) · $749k sold · 2026-08-18The Form 4 filing states the sale was made pursuant to a "10b5-1 plan (stated on the filing)".
Form 4 · Jones Nicole S (See Remarks) · $749k sold · 2026-08-18Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The filings show a trailing twelve-month price-to-earnings (P/E) ratio of 11.21.
Valuation inputs · SEC XBRL + stored EOD closeThe filings show a trailing twelve-month enterprise-value-to-EBITDA (EV/EBITDA) multiple of 8.57, with EBITDA (TTM) of 12,602,000,000 and enterprise value of 108,020,911,967.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score — the argument is shown, not hidden, so you can judge the reasoning yourself.
Several company-level fundamentals show meaningful improvement: revenues, operating income, and diluted EPS all rose between the fiscal Q1 2025 and fiscal Q2 2026 periods, while reported common shares outstanding declined—supporting higher per-share earnings power. Valuation signals in the evidence set (trailing P/E ~11.2 and EV/EBITDA ~8.6) combined with modest dividend yield and visible ETF/index inclusion point to relative valuation and income context versus the universe. Market technicals (a recent golden cross with price near the 50- and 200-day SMAs) and small positive momentum readings add an observational layer of price-based confirmation in the near term. The strongest bearish points (insider sales, historical drawdown, and limited parsed filings) rely on thin or incomplete parsing and/or reflect historical patterns; the insider sale is documented as executed under a 10b5-1 plan in the evidence, and the drawdown measure is a historical fact that does not negate the contemporaneous fundamentals and valuation inputs.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.33
36 surviving claims rest on 17 distinct sources; the heaviest analyst carries 19% of them, and 97% of what the desk raised survived the debate.
The surviving evidence set is moderately robust: 36 upheld claims draw on 17 distinct sources, which helps reduce single-source failure risk, but one analyst accounting for 19% of claims and a 97% survival rate through debate suggest confirmation pressure and limited critical pushback. Treat conclusions as informational signals that carry some concentration risk and potential overfitting to the desk’s prevailing view.
Peer context · computed, not argued
12-1 momentum ranks 4th of 4 in Healthcare Plans (as of 2026-09-01).
90-day volatility ranks 3rd of 4 in Healthcare Plans (as of 2026-09-01).
dividend yield ranks 3rd of 4 in Healthcare Plans (as of 2026-09-01).
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment — when the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here — no outside knowledge, no browsing — and each card shows who read it and what it contributed to the score.
19 filings· 1 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data — not retyped or estimated.
Read by Mercer+1.7 to the score
2 documents
SEC filing documents
The filings themselves, including the year-over-year comparison of Item 1A risk factors.
Read by Oakes+0.0 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash+0.4 to the score
3 holdings records· 1 cited
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.8 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
1 filing
Insider filings
Parsed Forms 3/4/5 from EDGAR: named insiders, share counts, prices, and 10b5-1 plan state — stated and inferred flags kept apart.
Read by Talbot−0.7 to the score
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only — it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal — the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
Get this for the tickers you actually hold
Plus the one thing no sample can show: how each name correlates with your portfolio, and what hides inside your funds.
The full terminal on CI Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.